Comparison of Circulating Tumor Cells and AR-V7 As Clinical Biomarker in Metastatic Castration-resistant Prostate Cancer Patients

Overview

Journal Sci Rep

Specialty Science

Date 2022 Jul 13

PMID 35831403

Authors

Katrin Schlack

Konstantin Seitzer

Neele Wustmann

Verena Humberg

Norbert Grundmann

Julie Steinestel

Dorothee Tiedje

Kambiz Rahbar

Laura-Maria Krabbe

Martin Bogemann

Andres J Schrader

Christof Bernemann

Affiliations

Soon will be listed here.

Abstract

Biomarker in metastatic castration resistant prostate cancer (mCRPC) treatment are rare. We aimed to compare the clinical value of circulating tumor cells (CTCs) and androgen receptor splice variant 7 (AR-V7) as biomarker in mCRPC patients undergoing androgen receptor-targeted agent (ARTA) treatment. Overall cohort (65 patients) was stratified regarding either CTC or AR-V7 status followed by further sub-stratification of the respective other marker. Subsequently, prostate specific antigen (PSA) response, progression free survival (PFS) and overall survival (OS)) of subgroups was compared. CTCs and AR-V7 were detected in 54 (83%) and 33 (61%) patients, respectively. All AR-V7 + were CTC +. We detected PSA response in all subgroups. For PFS and OS, biomarker stratification revealed differences between all subgroups. Interestingly, no significant differences of AR-V7 transcript copy numbers were detected between responding and non-responding patients. Additionally, multivariable analysis revealed no independent prognostic value of AR-V7 positivity. Both biomarkers show clinical value in prognosticating clinical outcome. Nonetheless, AR-V7 stratification underestimates the heterogenous subgroup of CTC - and CTC + patient, the latter requiring more intense clinical surveillance. Additionally, AR-V7 level does not correlate with clinical response. Thus, the value of AR-V7 as a clinical biomarker must be considered skeptically.

Citing Articles

The impact of androgen-induced translation in modulating androgen receptor activity.

Israel J, Marcelin L, Mehralivand S, Scholze J, Hofmann J, Stope M Biol Direct. 2024; 19(1):111.

PMID: 39529201 PMC: 11555926. DOI: 10.1186/s13062-024-00550-6.

Genetic Variations in , and in a Selected Sample of Slovak Patients With Metastatic Castration-resistant Prostate Cancer.

Holeckova K, Hives M, Grendar M, Drobkova H, Kliment Sr J In Vivo. 2024; 38(6):2610-2616.

PMID: 39477439 PMC: 11535959. DOI: 10.21873/invivo.13737.

New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium.

Mehralivand S, Thomas C, Puhr M, Claessens F, van de Merbel A, Dubrovska A J Transl Med. 2024; 22(1):71.

PMID: 38238739 PMC: 10795409. DOI: 10.1186/s12967-024-04878-5.

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer.

Wustmann N, Seitzer K, Humberg V, Vieler J, Grundmann N, Steinestel J Biomark Res. 2023; 11(1):37.

PMID: 37016463 PMC: 10074820. DOI: 10.1186/s40364-023-00481-w.

Novel, alternative splicing signature to detect lymph node metastasis in prostate adenocarcinoma with machine learning.

Xie P, Batur J, An X, Yasen M, Fu X, Jia L Front Oncol. 2023; 12:1084403.

PMID: 36713568 PMC: 9880415. DOI: 10.3389/fonc.2022.1084403.

References

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Allard W, Terstappen L . CCR 20th Anniversary Commentary: Paving the Way for Circulating Tumor Cells. Clin Cancer Res. 2015; 21(13):2883-5. DOI: 10.1158/1078-0432.CCR-14-2559. View

Heidrich I, Ackar L, Mohammadi P, Pantel K . Liquid biopsies: Potential and challenges. Int J Cancer. 2020; 148(3):528-545. DOI: 10.1002/ijc.33217. View

Scher H, Morris M, Stadler W, Higano C, Basch E, Fizazi K . Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016; 34(12):1402-18. PMC: 4872347. DOI: 10.1200/JCO.2015.64.2702. View

Bernemann C, Humberg V, Thielen B, Steinestel J, Chen X, Duensing S . Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer. Clin Cancer Res. 2019; 25(13):3856-3864. DOI: 10.1158/1078-0432.CCR-18-4276. View

To S, Kwan E, Fettke H, Mant A, Docanto M, Martelotto L . Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018; 73(6):818-821. DOI: 10.1016/j.eururo.2018.01.007. View

Armstrong A, Luo J, Nanus D, Giannakakou P, Szmulewitz R, Danila D . Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2020; 4. PMC: 7608579. DOI: 10.1200/PO.20.00200. View

Gillessen S, Attard G, Beer T, Beltran H, Bjartell A, Bossi A . Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020; 77(4):508-547. DOI: 10.1016/j.eururo.2020.01.012. View

Bernemann C, Steinestel J, Humberg V, Bogemann M, Schrader A, Lennerz J . Performance comparison of two androgen receptor splice variant 7 (AR-V7) detection methods. BJU Int. 2018; 122(2):219-226. DOI: 10.1111/bju.14146. View

10.

Seitz A, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M . AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. Eur Urol. 2017; 72(5):828-834. DOI: 10.1016/j.eururo.2017.07.024. View

11.

Antonarakis E, Lu C, Wang H, Luber B, Nakazawa M, Roeser J . AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371(11):1028-38. PMC: 4201502. DOI: 10.1056/NEJMoa1315815. View

12.

Scher H, Heller G, Molina A, Attard G, Danila D, Jia X . Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol. 2015; 33(12):1348-55. PMC: 4397279. DOI: 10.1200/JCO.2014.55.3487. View

13.

Scher H, Graf R, Schreiber N, Jayaram A, Winquist E, McLaughlin B . Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncol. 2018; 4(9):1179-1186. PMC: 6139066. DOI: 10.1001/jamaoncol.2018.1621. View

14.

Taplin M, Antonarakis E, Ferrante K, Horgan K, Blumenstein B, Saad F . Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019; 76(6):843-851. DOI: 10.1016/j.eururo.2019.08.034. View

15.

Miller M, Doyle G, Terstappen L . Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol. 2009; 2010:617421. PMC: 2793426. DOI: 10.1155/2010/617421. View

16.

Armstrong A, Halabi S, Luo J, Nanus D, Giannakakou P, Szmulewitz R . Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J Clin Oncol. 2019; 37(13):1120-1129. PMC: 6494355. DOI: 10.1200/JCO.18.01731. View

17.

Heller G, McCormack R, Kheoh T, Molina A, Smith M, Dreicer R . Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. J Clin Oncol. 2017; 36(6):572-580. PMC: 5815402. DOI: 10.1200/JCO.2017.75.2998. View

18.

Scher H, Lu D, Schreiber N, Louw J, Graf R, Vargas H . Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncol. 2016; 2(11):1441-1449. PMC: 5206761. DOI: 10.1001/jamaoncol.2016.1828. View

19.

Miyamoto D, Zheng Y, Wittner B, Lee R, Zhu H, Broderick K . RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015; 349(6254):1351-6. PMC: 4872391. DOI: 10.1126/science.aab0917. View

20.

Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M . Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. Eur Urol. 2016; 70(6):985-992. PMC: 5568108. DOI: 10.1016/j.eururo.2016.05.023. View